It is believed that the mechanism of NAC action in myocardial infarction and HF relies on ROS inhibition, antiplatelet, anti-inflammatory, and anti-apoptotic activity, reduction in obesity-related cardiac insulin resistance, as well as inhibition of angiotensin-converting enzyme (ACE) [140]. The gene discussed is ACE; the disease is obesity due to melanocortin 4 receptor deficiency.